ICU Medical, Inc. — FY 2012 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2012; it also reports fourth-quarter results. ICU Medical develops and manufactures medical devices for infusion therapy, critical care and oncology, selling through manufacturers, distributors and direct channels. Its largest customer, Hospira, accounted for 42% of FY 2012 revenue. The company reported one business segment.
Financial performance and position
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Total revenue | $316.9 million | $302.2 million |
| Gross profit / gross margin | $156.5 million / 49% | $142.4 million / 47% |
| Operating income / margin | $61.3 million / 19% | $65.2 million / 22% |
| Net income | $41.3 million | $44.7 million |
| Diluted EPS | $2.80 | $3.15 |
| Cash provided by operations | $66.3 million | $64.5 million |
| Cash, cash equivalents and investments at year-end | $226.2 million | $160.0 million |
| Working capital at year-end | $296.4 million | $231.1 million |
Capital expenditures were $19.2 million; investing activities used $41.4 million, including net investment purchases. Financing activities provided $21.6 million, primarily from employee stock-option exercises and related tax benefits. The balance sheet reports no borrowings or other financial debt. Total assets were $428.5 million and stockholders’ equity was $390.9 million. The company said existing cash, investments and expected operating cash flow should fund operations for at least the next 12 months.
Fourth quarter: Revenue was $82.7 million, versus $76.5 million in Q4 2011; net income was $12.3 million, versus $17.8 million; diluted EPS was $0.82, versus $1.26. The prior-year quarter included the $14.2 million gain on sale of the Orbit product line, which makes the earnings comparison unusually favorable to 2011.
Material changes versus prior year
- Revenue grew 4.9%. Infusion therapy sales rose 8% to $215.3 million; oncology sales increased 24% to $30.3 million. Critical care sales fell 10% to $55.5 million, mainly due to competition, lower unit sales and pricing pressure.
- Clave products represented 37% of revenue, up from 36%; custom infusion sets represented 27%, up from 25%. Hospira remained the largest customer at 42% of revenue.
- Gross margin improved by about two percentage points, attributed to product mix, favorable Mexican peso exchange rates and plant efficiencies. R&D expense increased to $10.6 million from $8.6 million.
- Operating income and net income declined year over year in part because 2011 included a $14.2 million Orbit asset-sale gain and $2.5 million legal-settlement income. The Orbit product line was sold in November 2011.
- Cash and investments rose $66.2 million. The company repurchased no shares in 2012; $28.1 million remained under its $40 million repurchase authorization.
Outlook, commentary and risks
- Management expected modest 2013 growth in infusion therapy and international sales, significant oncology growth, and lower critical care sales. It expected Hospira U.S. sales to be comparable to or slightly below 2012, with a planned first-quarter order reduction; these estimates were not guaranteed.
- Management estimated 2013 capital expenditures of $30–$35 million, including a Salt Lake City manufacturing-space conversion and new clean room. It expected SG&A at about 27% of revenue, R&D at about 3%, and an effective tax rate near 34%.
- Key exposures include reliance on Hospira and its sales channels; competition and pricing pressure; manufacturing concentration and disruption risks in Salt Lake City, Mexico and Slovakia; supplier availability and input costs; foreign-exchange and international credit risks; and regulatory, product-liability and product-recall risks.
- The 2.3% U.S. medical-device excise tax took effect January 1, 2013. The company also noted Medicare limits on dialysis catheter use, which could pressure TEGO sales.
- Clave-related U.S. patents were scheduled to begin expiring in 2014. In the RyMed patent case, a jury found infringement and patent validity, but a defense remained pending; damages, if any, had not yet been determined.
- The company had $79.3 million of investment securities, described as investment grade, and did not hedge foreign-exchange exposure. A 10% euro exchange-rate movement was estimated to affect specified balance-sheet net assets by about $6.0 million; a 10% Mexican peso movement was estimated to affect cost of goods sold by about $2.2 million.
- Independent auditors issued unqualified opinions on the financial statements and internal control over financial reporting.
Investor verification checklist
- Assess the durability of Hospira’s 42% revenue contribution, the terms and performance of the agreements extending through 2018, and the planned 2013 order pattern.
- Verify whether infusion and oncology growth can offset continued critical-care declines and competitive price pressure.
- Track gross-margin sustainability, manufacturing efficiencies, and the execution and returns from planned $30–$35 million capital spending.
- Review the outcome and potential financial impact of the RyMed litigation, upcoming patent expirations, and any resulting competitive or pricing changes.
- Monitor implementation costs of the medical-device excise tax, currency exposure, international receivables and customer concentration.